Skip to main content
Evidence Snapshot

5'-nucleotidase

CHEMBL5957 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5957
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5'-nucleotidase as ChEMBL target CHEMBL5957, mapped to UniProt P21589. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5'-nucleotidase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5957
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21589
5'-nucleotidase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5'-nucleotidase matters

As of 2026-09-13

5'-nucleotidase is reviewed as 5'-nucleotidase (UniProt P21589); 5'-nucleotidase shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 1236 compounds, and 173 assays, with lead potency reaching pChEMBL 11.0.

Disease context
non-small cell lung carcinoma

5'-nucleotidase shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include OLECLUMAB.

Start review with non-small cell lung carcinoma because it currently carries late clinical support. Linked drugs include OLECLUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 0 approved drugs, 1236 compounds, and 173 assays for this target. The dominant activity type is IC50. CHEMBL4761506 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4761506 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5'-nucleotidase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P21589, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why non-small cell lung carcinoma is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1236
Total Compounds
173
Total Assays
0
Approved Drugs
IC50: 1812.0, KI: 140.0, EC50: 8.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4761506
 11.0 IC50 —
No preferred name
CHEMBL4471306
 11.0 IC50 Clinical
No preferred name
CHEMBL5431118
 10.9 IC50 —
No preferred name
CHEMBL4749428
 10.6 IC50 —
No preferred name
CHEMBL4776758
 10.6 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5957